Loading...
•
Mar 31, 2024
Glaukos Q1 2024 Earnings Report
Glaukos' Q1 2024 financial performance was announced, featuring record net sales and progress in advancing novel dropless platform technologies.
Key Takeaways
Glaukos reported record net sales of $85.6 million in Q1 2024, a 16% increase year-over-year. The company raised its 2024 net sales guidance to $357 to $365 million. Gross margin was approximately 76%, and non-GAAP gross margin was approximately 83%.
Record net sales reached $85.6 million, a 16% increase year-over-year.
Glaucoma net sales hit a record $67.2 million, up 20% year-over-year.
Corneal Health net sales increased by 4% year-over-year, reaching $18.4 million.
The company raised 2024 net sales guidance to $357 to $365 million.
Glaukos
Glaukos
Glaukos Revenue by Segment
Glaukos Revenue by Geographic Location
Revenue by Segment
Glaucoma Revenue
CapyFin.comRevenue by Geographic Location
U.S. Glaucoma Revenue
CapyFin.comInternational Glaucoma Revenue
CapyFin.com Forward Guidance
The company expects 2024 net sales to be in the range of $357 million to $365 million based on the latest foreign currency exchange rates.